In the current session, Hims & Hers Health Inc. (NYSE:HIMS) is trading at $15.60, after a 0.22% drop. Over the past month, the stock fell by 47.46%, and in the past year, by 60.88%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. A Look at Hims & Hers Health P/E Relative to Its CompetitorsThe P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, ...

Now, Hims and Hers is set to report earnings after the close today. So, to help us preview the results, I'd now like to welcome in our next guest, Raul Shaw, CEO of Doc Shaw Financial. And so, Raul will thank you so much for kicking off this week with us, what are your overall expectations for him and hers given the fact that this name has has taken it on the chin a bit this year.I mean, we're down 54% since the start of 2026. >> We are down quite a bit. And before I get into everything, you know, Jenny, it ...

Hims & Hers app and GLP-1 injection kit on a desk, highlighting weight-loss demand and HIMS stock focus. Key Points Shares of HIMS have plummeted 75% from their May 2025 highs, recently driven by a Novo Nordisk lawsuit filed on Feb. 9. The stock’s Relative Strength Index reading of 16.87 is absurdly low, suggesting it is oversold. Analysts are optimistic that a rebound is coming, with the average 12-month price target implying nearly 150% potential upside. Interested in Hims & Hers Health, Inc.? Here ...

Core Insights - Retail investors have shown significant interest in five stocks: Super Micro Computer Inc. (SMCI), Hims & Hers Health Inc. (HIMS), Blue Owl Capital Inc. (OWL), Microsoft Corp. (MSFT), and Walmart Inc. (WMT), driven by factors such as retail hype, earnings, AI buzz, and corporate news flow [1] Super Micro Computer Inc. (SMCI) - Retail investors are highly bullish on SMCI, with some jokingly considering betting their entire portfolio on the stock for the upcoming months [7] - The stock has a 52-week range of $27.60 to $62.47, currently trading around $32 to $35 per share, and has fallen 45.74% over the year and 24.52% over the last six months [7] - SMCI exhibits a weaker price trend across all time frames but has a strong growth ranking according to Benzinga's Edge Stock Rankings [7] Hims & Hers Health Inc. (HIMS) - Retail investors believe HIMS could surpass the $20 mark, despite its current trading range of $15 to $16 per share [7] - The stock has a 52-week range of $15.46 to $70.43 and has declined by 76.18% over the year and 63.53% in the last six months [7] - HIMS shows a weaker price trend in all time frames and has a poor value ranking according to Benzinga's Edge Stock Rankings [7] Blue Owl Capital Inc. (OWL) - Retail investors are concerned about the withdrawal limit associated with OWL, which is currently trading around $11 to $13 per share [7] - The stock has a 52-week range of $10.88 to $23.98 and has declined 49.87% over the year and 37.64% in the last six months [7] - OWL has a weaker price trend across all time frames but maintains a solid growth score according to Benzinga's Edge Stock Rankings [7] Microsoft Corp. (MSFT) - Retail sentiment towards MSFT has turned sour, with the stock trading around $398 to $400 per share [7] - The stock has a 52-week range of $344.79 to $555.45 and is down 4.25% over the year and 21.21% over the last six months [7] - MSFT shows a weaker price trend across all time frames but has a solid quality score according to Benzinga's Edge Stock Rankings [7] Walmart Inc. (WMT) - Some retail investors believe that WMT's decline could lead to a rotation back into tech stocks, with the stock currently trading around $124 to $125 per share [7] - The stock has a 52-week range of $79.85 to $134.69 and has returned 28.45% over the year and the last six months [7] - WMT maintains a stronger price trend across all time frames and has a solid quality ranking according to Benzinga's Edge Stock Rankings [8]

Core Insights - Hims & Hers Health, Inc. (HIMS) is establishing itself as a leading digital health platform focused on personalized, technology-enabled care, expanding its offerings across various life stages and health conditions [1][8] - The company has launched new specialties in women's health, including menopause and perimenopause, and in men's health with a low testosterone category, providing tailored treatment plans [1][8] - Hims & Hers is advancing into proactive, data-driven care with the introduction of Labs for comprehensive health monitoring and a multi-cancer early detection blood test [2][8] Company Developments - Hims & Hers has introduced a dedicated menopause and perimenopause specialty on the Hers platform, along with a low testosterone category on the HIMS platform, enhancing its service offerings [1][8] - The launch of Labs allows customers to monitor key health markers over time, supported by provider-guided action plans, and includes a multi-cancer early detection blood test for over 50 cancer types [2][8] - The company is making strategic investments in AI, diagnostics, and global expansion to create a connected healthcare platform that prioritizes personalized, preventive care [2][8] Financial Performance - Hims & Hers shares have decreased by 67.9% over the past year, underperforming the industry average decline of 32.8% [7] - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 indicates a significant improvement of 77.8% compared to 2024 [9] - HIMS' forward 12-month price-to-sales ratio is 1.3X, which is lower than the industry average of 3.7X and its five-year median of 2.7X, reflecting a Value Score of C [11]

7,111,969-$1.715.45%$29.68[Oracle][ORCL]• Vol: 10,510,788-$6.123.91%$150.43[Copart][CPRT]• Vol: 10,973,155-$1.473.90%$36.18[Newmont][NEM]• Vol: 5,055,402-$4.533.61%$120.87 Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills? - 24/7 Wall St.[S&P 5006,905.00 +0.65%][Dow Jones49,505.00 +0.28%][Nasdaq 10025,049.60 +1.07%][Russell 20002,662.73 +0.01%][FTSE 10010,708.60 +0.26%][Nikkei 22557,158.00 +0.12%][Stock Market Live February 20, 2026: S&P 500 (SPY) Sinks on US GDP Numbers][Investing]# ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Earnings Reports - A variety of companies are set to announce quarterly results, including Domino's Pizza, C3.ai, Dell Technologies, Home Depot, Nvidia, Salesforce, and others [2] Economic Data Releases - Key economic data to be released includes factory orders, the S&P Case-Shiller home price index, wholesale inventories, consumer confidence data, and the producer price index (PPI) for January [3][4] Federal Reserve Speeches - Several Federal Reserve officials, including Christopher Waller, Austan Goolsbee, Raphael Bostic, and Lisa Cook, are scheduled to deliver speeches throughout the week [3]

Key Takeaways Hims & Hers is set to post Q4 2025 results, with revenue projected to rise 28.7% year over year.Hims & Hers expanded into low testosterone, menopause care and Labs, boosting subscriber growth.HIMS faces higher marketing and operating costs plus compounded semaglutide legal scrutiny from Novo Nordisk.Hims & Hers Health, Inc. (HIMS) is scheduled to report fourth-quarter 2025 results on Feb. 23, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of 6 cents ...

Core Viewpoint - Hims & Hers Health Inc is facing significant challenges, with its stock near 17-month lows despite a recent acquisition of Eucalyptus for $1.15 billion and plans for global expansion [1][2]. Group 1: Stock Performance - Shares of Hims & Hers Health have experienced volatile performance, dropping 90% from a record high of $72.98 on February 19, and currently trading at $15.91 [1][2]. - The stock has only seen two gains in the last 14 trading sessions, indicating a prolonged period of underperformance [2]. Group 2: Market Indicators - The stock's 14-day Relative Strength Index (RSI) is at 10.2, indicating it is deeply in "oversold" territory, suggesting a potential for a short-term bounce [2]. - Short interest in Hims & Hers Health has increased by 14.4% over the past two reporting periods, now representing approximately 37.5% of the stock's available float [3].